Table 4.
Univariate and multivariate analyses of factors associated with a CD4 count <200 cells/µL after ≥6 months of ARV treatment (n = 302).
| Univariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|
| Odds ratio (95% CI) | P-value | Odds ratio (95% CI) | P-value | |
| Anemia | 2.53 (1.33–4.81) | 0.005 | – | – |
| Leukopenia | 7.98 (3.73–17.11) | <0.001 | 7 (2.88–17.04) | <0.001 |
| Thrombocytopenia | 0.90 (0.08–10.09) | 0.934 | – | – |
| Use of Azithromycin | 9.92 (5.72–17.17) | <0.001 | 4.91 (2.48–9.75) | <0.001 |
| Use of Cotrimoxazole | 9.63 (5.25–17.65) | <0.001 | 3.56 (1.69–7.49) | 0.001 |
| Age | 0.99 (0.95–1.02) | 0.400 | – | – |
| Male | 1.28 (0.35–4.64) | 0.707 | – | – |
| Single | 1.63 (0.63–4.25) | 0.315 | – | – |
| Employed | 0.64 (0.39–1.04) | 0.071 | – | – |
| Co-infection | ||||
| Hepatitis B | 0.69 (0.33–1.44) | 0.324 | – | – |
| Hepatitis C | 0.31 (0.04–2.62) | 0.282 | – | – |
| ARV regimen | ||||
| Lamivudine | – | – | – | – |
| Efavirenz | 1.19 (0.52–2.71) | 0.685 | – | – |
| Tenofovir | 0.86 (0.50–1.49) | 0.599 | – | – |
| Zidovudine | 1.12 (0.65–1.92) | 0.680 | – | – |
| Nevirapine | 0.89 (0.39–2.05) | 0.789 | – | – |
| Lopinavir | 0.95 (0.09–10.62) | 0.968 | – | – |
| Ritonavir | 0.95 (0.09–10.62) | 0.968 | – | – |
| Stavudine | – | – | – | – |
ARV: antiretroviral.
The p-values in bold are the ones that are statistically significant.